NXTC Q1 2019 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

-$5M-380.0% margin

Operating Income

-$7M-502.2% margin

Net Income

-$6M-453.6% margin

EPS (Diluted)

$-3.25

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$383,000

Balance Sheet

Total Assets

$145M

Total Liabilities

$198M

Stockholders' Equity

-$53M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	-$5M	-$4M	-22.5%
Operating Income	-$7M	-$5M	-36.1%
Net Income	-$6M	-$5M	-23.2%